Search Results

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

Over 80% of those living outside of biopharma’s biggest hubs, like San Diego or Boston, have a tough time finding work, according to a BioSpace LinkedIn poll. Biopharma professionals in Oregon and Connecticut and a BioSpace recruitment manager share their insights on this issue.

RedHill Biopharma Ltd. investors for the purchase and sale of 10,000,000 of the Company’s American Depositary Shares (“ADSs”) at a purchase price of $0.80 per ADS, in a registered direct offering.

Nearly half of BioSpace poll respondents recently took a biopharma job they were overqualified for, a finding that didn’t surprise a talent acquisition expert, who said it’s become much more likely to happen.

2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

RedHill Biopharma Ltd. announced that it has closed its previously announced registered direct offering for the purchase and sale of 10,000,000 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, at a purchase price of $0.80 per ADS.

RedHill Biopharma Ltd. announced that it has entered into definitive agreements with private investors for the purchase and sale, at a premium, of 2,144,487 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, par value NIS 0.01 per share, of the Company, and warrants to purchase up to an aggregate of 2,144,487ADSs, at a purchase price of $0.58289 per ADS and accompanying warrant, in a registered direct offering.

As they navigate a competitive job market, biopharma professionals are making four key interview mistakes, according to two talent acquisition experts. They discuss those errors and offer tips for how to get those critical conversations right.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their pipelines with novel and potentially more effective therapies.